Clinical Trials
33 trialsStudy of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan Kettering Cancer Center
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
ABILITY-1
Medicenna Therapeutics, Inc.
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
A Study of MT027 in Patients with Pleural Malignant Tumors
Suzhou Maximum Bio-tech Co., Ltd.
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
REGOMUNE
Institut Bergonié
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
First-in-human Study of S-588210 (S-488210+S-488211)
Shionogi Inc.
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Jonsson Comprehensive Cancer Center
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
National Cancer Institute (NCI)
Rapamycin With Grapefruit Juice for Advanced Malignancies
University of Chicago
MesoVATS
Papworth Hospital NHS Foundation Trust
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
National Institutes of Health Clinical Center (CC)
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Pediatric Brain Tumor Consortium
IPHC
Wuhan University